Celltrion is a global pharmaceutical company, fully vertically integrated from R&D through to commercialization. We focus on developing and bringing to market innovative biopharmaceuticals across more than 100 countries. In Canada, Celltrion currently offers over 10 Health Canada–approved molecules, including infliximab, adalimumab, and ustekinumab. With a robust pipeline, our offerings for Canadian patients will continue to expand. Our patient support program, Celltrion Connect, provides personalized assistance to ensure optimal treatment outcomes for Canadian patients. To learn more about our vision and pipeline, please visit the Celltrion Healthcare Canada website